We are live on ! Find out more
AIM

Alerce Investment Management Portfolio holdings

AUM $56.8M
1-Year Est. Return 31.17%
This Fund
S&P 500
This Quarter Est. Return
-7.11%
1 Year Est. Return
+31.17%
3 Year Est. Return
+25.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$86.9M
AUM Growth
-$16.9M
Cap. Flow
-$4.44M
Cap. Flow %
-5.11%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
3
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
AMWL icon
American Well
AMWL
+$12.2M
2
WHWK
Whitehawk Therapeutics
WHWK
+$4.39M
3
AKBA icon
Akebia Therapeutics
AKBA
+$3.27M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$24.3M
2
RNTX
Rein Therapeutics
RNTX
+$20

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMWL icon
1
American Well
AMWL
$180M
$29.6M 34.1%
523,786
+168,747
+48% +$12.2M
ANNX icon
2
Annexon
ANNX
$834M
$22.8M 26.22%
4,408,966
– –
WHWK
3
Whitehawk Therapeutics
WHWK
$190M
$20.9M 24.07%
1,630,830
+336,045
+26% +$4.39M
AKBA icon
4
Akebia Therapeutics
AKBA
$354M
$8.71M 10.02%
15,090,119
+10,437,558
+224% +$3.27M
ASMB icon
5
Assembly Biosciences
ASMB
$498M
$2.9M 3.33%
185,625
– –
RNTX
6
Rein Therapeutics
RNTX
$63.1M
$1.97M 2.26%
830,466
-6
-0% -$20
GBT
7
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-356,270
Closed -$24.3M

Similar funds

CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
AFA
Atlas Financial Advisors Oroville, California $64.1M AUM 8.36% 1-Year Est. Return
MCC
Maiden Cove Capital Cape Elizabeth, Maine $65.4M AUM
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
MC
Meketa Capital Westwood, Massachusetts $44.6M AUM
OAM
Origin Asset Management London, United Kingdom $43.5M AUM 31.63% 1-Year Est. Return
IP
Isomer Partners New York $74.3M AUM 23.95% 1-Year Est. Return
JCP
Jennifer C. Price $75.5M AUM 6.25% 1-Year Est. Return

Alerce Investment Management's Q4 2022 Portfolio in Review

As of Q4 2022, Alerce Investment Management held 7 positions worth $86.9M, down 16% from $104M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Alerce Investment Management withdrew a net $4.44M in Q4 2022, closing 1 position and reducing 1 holding. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $24.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Alerce Investment Management added an estimated $12.2M to American Well.

  • Alerce Investment Management added most to American Well in Q4 2022, an estimated $12.2M increase.
  • Alerce Investment Management's biggest Q4 2022 reduction was Rein Therapeutics, cutting an estimated $20.
  • Alerce Investment Management fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $24.3M.
  • Alerce Investment Management's ten largest holdings make up 100% of its $86.9M portfolio in Q4 2022.
  • Alerce Investment Management opened 0 new positions and closed 1 in Q4 2022.
  • Alerce Investment Management's portfolio value fell 16% quarter-over-quarter to $86.9M.

Based on Alerce Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.